Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

AAC Holdings, Inc. Reports Fourth Quarter and Full Year 2017 Results

AAC Holdings
Posted on: 24 Feb 18

BRENTWOOD, Tenn., Feb. 21, 2018 /PRNewswire/ -- Today AAC Holdings, Inc. (NYSE: AAC) announced financial results for the fourth quarter and year ended December 31, 2017.

Fourth Quarter 2017 Operational and Financial Highlights:
(All comparisons are to the comparable prior-year period, unless otherwise noted)

Total revenue increased 19% to $86.1 million

Average daily residential revenue (ADR) increased 58% to $1,054 and average revenue per outpatient visit (ARV) increased 16% to $418

Total average daily census (ADC) increased to 995 compared with 962

Outpatient visits increased 37% to 21,651

Net loss available to AAC Holdings, Inc. common stockholders was $18.8 million, or ($0.80) per diluted common share, including a charge of $23.3 million or ($0.70) per diluted common share, for estimated legal settlement costs and a charge of $3.5 million, or ($0.15) per diluted common share, related to the estimated impact of the Tax Cuts and Jobs Act on net deferred tax assets.

Adjusted EBITDA increased 35% to $15.1 million (see non-GAAP reconciliation herein)

Adjusted earnings per diluted common share was $0.10 compared with $0.15 per diluted common share (see non-GAAP reconciliation herein)

Days sales outstanding (DSO) decreased by 10 days to 101

"Our strong fourth quarter capped off a year of solid performance, providing excellent momentum as we head into the new year. In 2017, we expanded our outpatient and sober living offerings, consolidated facilities in Southern California, Southern Florida and Louisiana to accelerate operational efficiencies, increased our borrowing capacity with a new $210 million secured term loan facility and a $55 million revolving credit facility, and announced the pending acquisition of AdCare," said Michael Cartwright, Chairman and Chief Executive Officer of AAC Holdings, Inc. "Of course, delivering excellent clinical client care remains our top focus, and our effectiveness in executing against this vision is illustrated in the recent findings of our 12-month clinical outcomes study and in investments we are making in clinical and other technology to further improve client experiences, safety and outcomes."

Fourth Quarter 2017 Financial Results

AAC breaks down its revenues between client related revenue and non-client related revenue. Client related revenue includes: (1) residential treatment facility services and related professional services; (2) outpatient facility services, related professional services and sober living services; and (3) client related diagnostic services, which includes point of care drug testing and client related diagnostic laboratory services. Non-client related revenue includes marketing and diagnostic services provided to third parties. Prior period results have been conformed to the current period presentation.

Total revenue increased 19% to $86.1 million compared with $72.4 million in the same period in the prior year.

Residential treatment facility revenue increased 40% to $71.5 million compared with $51.2 million in the same period in the prior year. ADR increased 58% to $1,054 compared with $667 in the same period in the prior year.

Outpatient and sober living facility revenue increased 59% to $9.0 million compared with $5.7 million in the same period in the prior year. ARV increased 16% to $418 compared with $360 in the same period in the prior year.

Client related diagnostic services revenue was down 78% to $3.1 million compared with $14.2 million in the same period in the prior year. The decrease in client related diagnostic services is a result of previously anticipated lower reimbursements combined with a shift in the mix of client related diagnostic services from higher reimbursed tests to lower reimbursed tests.

Non-client related revenue increased 104% to $2.5 million compared with $1.2 million in the same period in the prior year.

Net loss available to AAC Holdings, Inc. common stockholders was $18.8 million, or ($0.80) per diluted common share, compared with net income available to AAC Holdings, Inc. common stockholders of $0.5 million, or $0.02 per diluted common share, in the prior-year period. Included in the net loss available to AAC Holdings, Inc. common stockholders is the accrued litigation liability of $23.3 million, or ($0.70) per diluted common share, related to the estimated settlement of the Tennessee class action litigation and the Nevada derivative litigation matters. Also included in the net loss available to AAC Holdings, Inc. common stockholders is a non-cash increase in the Company's provision for income taxes of $3.5 million, or ($0.15) per diluted common share, related to the estimated impact of the Tax Cuts and Jobs Act on the net deferred tax assets. These estimates may be refined as further information becomes available.

Adjusted EBITDA increased 35% to $15.1 million compared with $11.1 million for the same period in the prior year. Adjusted net income available to AAC Holdings, Inc. common stockholders decreased to $2.4 million, or $0.10 per diluted common share, compared with $3.4 million, or $0.15 per diluted common share, for the same period in the prior year. Adjusted EBITDA, adjusted net income available to AAC Holdings, Inc. common stockholders and adjusted diluted earnings per share are non-GAAP financial measures. Tables reconciling these non-GAAP measures to the most directly comparable GAAP measures are included at the end of this release.

Full Year 2017 Financial Results

Total revenue for the year ended December 31, 2017 increased 14% to $317.6 million compared with $279.8 million in the prior year.

Residential treatment facility revenue increased 30% to $247.0 million compared with $189.5 million in the prior year. ADR increased 38% to $873 compared with $633 in the prior year.

Outpatient and sober living facility revenue increased 74% to $29.1 million for the year ended December 31, 2107 compared with $16.7 million in the prior year. ARV increased 19% to $403 compared with $339 in the prior year.

Client related diagnostic services revenue was down 50% to $32.5 million compared with $64.4 million in the prior year. As is the case with fourth quarter results, this decrease is the result of previously anticipated lower reimbursements combined with a shift in the mix of client related diagnostic services from higher reimbursed tests to lower reimbursed tests.

Non-client related revenue decreased 1% to $9.1 million for the year ended December 31, 2017 compared with $9.2 million in the in the prior year.

Net loss available to AAC Holdings, Inc. common stockholders was $20.6 million, or ($0.88) per diluted common share, for the year ended December 31, 2017, compared with net loss available to AAC Holdings, Inc. common stockholders of $0.6 million, or ($0.03) per diluted common share, in the prior year. Included in the net loss available to AAC Holdings, Inc. common stockholders is an accrued litigation liability of $23.3 million, or ($0.70) per diluted common share, and the non-cash increase in the Company's provision for income taxes of $3.5 million, or ($0.15) per diluted common share, outlined above.

Adjusted EBITDA increased 20% to $57.1 million for the year ended December 31, 2017 compared with $47.7 million for the prior year. Adjusted net income available to AAC Holdings, Inc. common stockholders decreased to $13.9 million, or $0.60 per diluted common share, compared with $16.2 million, or $0.71 per diluted common share, for the same period in the prior year. Adjusted EBITDA, adjusted net income available to AAC Holdings, Inc. common stockholders and adjusted diluted earnings per share are non-GAAP financial measures. Tables reconciling these non-GAAP measures to the most directly comparable GAAP measures, are included at the end of this release.

Balance Sheet and Cash Flows

As of December 31, 2017, AAC Holdings' balance sheet reflected cash and cash equivalents of $13.8 million, net property and equipment of $152.5 million and total debt of $201.2 million, net of debt issuance costs of $7.2 million.

Cash flows provided by operations totaled $5.3 million for the fourth quarter of 2017 compared with cash flows used in operations of $1.2 million in the prior year period. Capital expenditures in the fourth quarter of 2017 totaled $5.9 million.

Days sales outstanding continue to improve and were 101 days for the fourth quarter of 2017 compared with 106 days for the third quarter of 2017 and 111 for the prior-year period. Total cash collections increased 15% for the year ended December 31, 2017 as compared to the year ended December 31, 2016.

2018 Outlook

In May 2014, the FASB issued Accounting Standards Codification (ASC) Topic 606, "Revenue from Contracts with Customers," a replacement of Revenue Recognition Topic 605. The Company adopted ASC 606 on January 1, 2018. Under ASC 606, the majority of the provision for doubtful accounts, which historically was reported as an operating expense, will now be reported as a direct reduction to revenue in 2018. This change in presentation will reduce revenues and operating expenses by the same amount and is not expected to have an effect on net income or earnings per share. 

For more information:
www.prnewswire.com/news-releases/aac-holdings-inc-reports-fourth-quarter-and-full-year-2017-results-300602378.html

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 24/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.